Companies

Ginkgo BioworksSummer 2014Public

Boston · MA, USA · founded 2014 · http://ginkgobioworks.com

Diligence memoA one-page analyst read on Ginkgo Bioworks — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 5%
Sector rank · raised
Latest stage · inferred

Ginkgo Bioworks: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Our mission is to make biology easier to engineer.

Ginkgo Bioworks is the organism company. We design custom organisms for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.

Synthetic BiologyDiagnosticsAutomation
Find Ginkgo Bioworks online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$1.3M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$14.6M

Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

Ginkgo Bioworks is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Lygos, Inc.
Lygos engineers yeast to convert sugar into high-value industrial…
BiotechSeries B$432.7M76%
Bugworks Research, Inc.BiotechnologySeries B$56.4M75%
Manifold Biotechnologies, Inc.BiotechnologySeries B$198.4M75%
Pando Bioscience
Gen-AI Designed Enzymes for Pharmaceutical Innovation
Biotech75%
Culture Biosciences Inc.
We grow cells for biotech companies.
BiotechnologySeries B$857.3M75%
Ambrosia Biosciences Inc.BiotechnologySeries A$63.8M75%
Synoligo Biotechnologies, Inc.BiotechnologySeries A$89.2M74%
Reshape Biotech
Robots that automate the everyday tasks of microbiologists.
Biotech74%
Frequently asked
What does Ginkgo Bioworks do and where is it based?
Ginkgo Bioworks is a private company, based in Boston, MA, USA. Our mission is to make biology easier to engineer.
Explore related

See where Ginkgo Bioworks sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Ginkgo Bioworks, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.